DURHAM, N.C., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.
| Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023) | ||
| Format: | Corporate Presentation | |
| Date: | Monday, March 6 | |
| Time: | 1:30 – 2:30 p.m. ET | |
| Webcast: | /webcast/cowen132/register.aspx?conf=cowen132&page=huma&url=https://wsw.com/webcast/cowen132/huma/2006214 | |
| Oppenheimer’s 33rd Annual Healthcare Conference (March 13-15, 2023) | ||
| Format: | Corporate Presentation | |
| Date: | Tuesday, March 14 | |
| Time: | 2:40 – 3:10 p.m. ET | |
| Webcast: | /webcast/oppenheimer27/register.aspx?conf=oppenheimer27&page=huma&url=https://wsw.com/webcast/oppenheimer27/huma/2774359 | |
Webcast replays will be available for at least 30 days following the presentations at https://investors.humacyte.com/news-events/events-and-presentations.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity, a portfolio of Human Acellular Vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Humacyte Media Contact:
Elizabeth Miller, M.D.
LifeSci Communications LLC
+1-646-791-9705
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.28 |
| Daily Change: | -0.21 -4.68 |
| Daily Volume: | 3,525,119 |
| Market Cap: | US$510.820M |
November 21, 2024 November 14, 2024 November 08, 2024 October 28, 2024 | |
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE
GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...
CLICK TO LEARN MORE
